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blasts in bone marrow or peripheral blood. This can be
explained by what Walter et al reprted, using next-genera-
tion sequencing, that the proportion of neoplastic marrow
cells is indistinguishable in MDS and secondary-AML even
with myeloblast count of zero. HCT can be performed in
those patients including older patients with promising
results.340
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Background: Busulfan crosses the blood-brain barrier and at
high doses can cause severe neurotoxicity, including seizures
that are most commonly tonic-clonic in character. When
Busulfan is used in the conditioning of patients undergoing
hematopoietic cell transplantation (HSCT), phenytoin, ben-
zodiazepines, or newer anticonvulsants such as levetir-
acetam are often used for seizure prophylaxis. Phenytoin is a
potent inducer of cytochrome P450 hepatic enzymes that
leads to higher clearance of Busulfan. Phenytoin is also
capable of altering cyclophosphamide levels by affecting its
metabolism and formation of hydroxy-cyclophosphamide
through uridine glucoronosyltransferase enzymes and may
also affect HSCT outcomes such as increased risk of sinusoi-
dal obstructive syndrome (SOS). In this report, we evaluated
the impact of levetiracetam versus phenytoin on effective-
ness of seizure prophylaxis and development of SOS in our
center.
Methods: We retrospectively reviewed Allogeneic HSCT
patients who received intravenous Busulfan for 4 days as part
of their conditioning regimen in our center between 2002
and 2013. Primary objective was to study the impact of
phenytoin and levetiracetam on effectiveness of seizure
prophylaxis and SOS. Demographics and disease-related
variables were collected.
Results: Between 2002 and 2013, 106 patients received
Busulfan intravenously once daily for 4 days as part of part of
their conditioning regimen for allogeneic HSCT. Median age
at diagnosis was 56 (range 19-73). Median OS for all patients
was 316 days. Of these 106 patients, seventy-seven patients
(73%) received a regimen that included both Busulfan and
Cyclophosphamide (BUCY),while twenty-nine patients (27%)
received a regimen that included both Busulfan and Fludar-
abine (FluBu).Median age of patientswho received BUCYwas
54 while median age of patients who received FluBu was 60.
Sixty-four (60%) patients received phenytoin while 42 (40%)
received levetiracetam. Of 106, none developed seizures.
Only two patients developed SOS; one who received BUCY
and got phenytoin as seizure prophylaxis and the other one
received FluBu and got levetiracetam as seizure prophylaxis.
Both patients were on Low molecular weight heparin.
Conclusion: In this small cohort from a single center where
Busulfan Kinetics is not monitored, there is low incidence of
SOSwhether using BUCYor FluBu as conditioning regimen and
without anydifference betweenphenytoin or levetiracetamon
effectiveness of seizure prevention or SOS incidence.341
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HCT is the only known curative treatment for MDS. Treat-
ment with the DNA methyltransferase inhibitor azacitidine
(aza) has been utilized prior to HCT for tumor debulking and
to slow leukemic progression. To discern the impact of aza
treatment, we retrospectively analyzed the post transplant
outcomes of 159 patients (pts) according to pre-HCT aza
exposure. Patients included those with a diagnosis of MDS or
CMML at any time point in their disease course and subse-
quently received a HCT. Eligible patients proceeded to HCT if
they had adverse disease features such as elevated IPSS risk,
treatment related MDS, progression or refractory disease.
Consecutive patients receiving a HCT from July 2004 and
May 2011 were evaluated. All obtained a myeloablative HCT
using ﬂudarabine and IV-busulfan [targeted to an AUC of
3500, 5300, 6000 or 7500]. GVHD prophylaxis was with
tacrolimus plus either methotrexate or sirolimus or myco-
phenolate mofetil. Those with mismatched donors also
received ATG.
Seventy pts, median age of 56.5 (24.8 e 71.6) years (yrs), did
not receive pre-transplant aza (NOAZA group). Forty ptswere
older than 55 yrs (57%). At diagnosis, IPSS risk was Low (4),
Int-1 (25), Int-2 (17), High (5), not evaluable (4) (NE), AML (6)
and CMML (9). Twenty-one had treatment related MDS and
15 had AML at one time. Donors included 28 match related
donors (MRD), 31 matched unrelated donors (MUD) and 11
mismatched unrelated donors (mMUD). Median follow-up of
surviving patients was 70.0 (29.7 e 106.6) months.
Eighty-nine pts, median age of 57.8 (25.6 e 73.8) yrs,
received a median of 4 (1-12) cycles of aza prior to HCT (YES
AZA group). Fifty-four (61 %) were older than 55 yrs. At
diagnosis, IPSS risk was Low (n¼4), Int-1 (n¼26), Int-2
(n¼32), High (n¼15), NE (n¼2), AML (n¼2) and CMML (n¼8).
Twenty-three had treatment related MDS and 11 had AML at
one point. Donors included MRD (n¼38), MUD (n¼40) and
mMUD (n¼11). Median follow-up of surviving patients was
48.3 (24.1 e 103.2) months.
Prior to allografting the number of marrow blasts in the No-
AZA vs Yes-AZA was: <5% (n¼41 vs 49), 5-10% (n¼12 vs 19),
11 e 20% (n¼10 vs 11), >20% (n¼3 vs 4) and CMML (n¼4 vs
6). All patients engrafted with no difference in engraftment
rates or toxicities between the groups. At 3 years, the RFS and
OS suggest improvement with preHCT AZA and approached
statistical signiﬁcance.
